 DALLAS, Aug. 16, 2021 PRNewswire -- Lantern Pharma NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharmas abstract titled LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer being held on September 29-30, 2021. 